Literature DB >> 35608452

Prostate-specific Membrane Antigen PET: Standard Imaging in Prostate Cancer.

Hossein Jadvar1.   

Abstract

Entities:  

Mesh：

Year:  2022        PMID： 35608452      PMCID： PMC9434807          DOI： 10.1148/radiol.221074

Source DB:  PubMed          Journal:  Radiology        ISSN： 0033-8419            Impact factor:   29.146


× No keyword cloud information.
  9 in total

1.  The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation.

Authors:  Andrea K Miyahira; Howard R Soule
Journal:  J Nucl Med       Date:  2021-10-21       Impact factor: 10.057

2.  Preoperative PSMA-PET/CT as a predictor of biochemical persistence and early recurrence following radical prostatectomy with lymph node dissection.

Authors:  D J H Baas; M Schilham; R Hermsen; J M S de Baaij; H J E J Vrijhof; R J Hoekstra; J P M Sedelaar; H V N Küsters-Vandevelde; M Gotthardt; C H W Wijers; J P van Basten; D M Somford
Journal:  Prostate Cancer Prostatic Dis       Date:  2021-09-01       Impact factor: 5.554

3.  Impact of 18F-DCFPyL PET on Staging and Treatment of Unfavorable Intermediate or High-Risk Prostate Cancer.

Authors:  Adriano Basso Dias; Antonio Finelli; Glenn Bauman; Patrick Veit-Haibach; Alejandro Berlin; Claudia Ortega; Lisa Avery; Ur Metser
Journal:  Radiology       Date:  2022-05-24       Impact factor: 29.146

4.  Appropriate Use Criteria for Prostate-Specific Membrane Antigen PET Imaging.

Authors:  Hossein Jadvar; Jeremie Calais; Stefano Fanti; Felix Feng; Kirsten L Greene; James L Gulley; Michael Hofman; Bridget F Koontz; Daniel W Lin; Michael J Morris; Steve P Rowe; Trevor J Royce; Simpa Salami; Bital Savir-Baruch; Sandy Srinivas; Thomas A Hope
Journal:  J Nucl Med       Date:  2021-09-30       Impact factor: 11.082

5.  Phase 3 multicenter randomized trial of PSMA PET/CT prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: study protocol.

Authors:  Shaojun Zhu; Nader Hirmas; Jeremie Calais; Matthias Eiber; Boris Hadaschik; Martin Stuschke; Ken Herrmann; Johannes Czernin; Amar U Kishan; Nicholas G Nickols; David Elashoff; Wolfgang P Fendler
Journal:  BMC Cancer       Date:  2021-05-07       Impact factor: 4.430

6.  Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer.

Authors:  Michael Xiang; Ting Martin Ma; Ricky Savjani; Erqi L Pollom; R Jeffrey Karnes; Tristan Grogan; Jessica K Wong; Giovanni Motterle; Jeffrey J Tosoian; Bruce J Trock; Eric A Klein; Bradley J Stish; Robert T Dess; Daniel E Spratt; Avinash Pilar; Chandana Reddy; Rebecca Levin-Epstein; Trude B Wedde; Wolfgang A Lilleby; Ryan Fiano; Gregory S Merrick; Richard G Stock; D Jeffrey Demanes; Brian J Moran; Hartwig Huland; Phuoc T Tran; Santiago Martin; Rafael Martinez-Monge; Daniel J Krauss; Eyad I Abu-Isa; Ridwan Alam; Zeyad Schwen; Thomas M Pisansky; C Richard Choo; Daniel Y Song; Stephen Greco; Curtiland Deville; Todd McNutt; Theodore L DeWeese; Ashley E Ross; Jay P Ciezki; Paul C Boutros; Nicholas G Nickols; Prashant Bhat; David Shabsovich; Jesus E Juarez; Natalie Chong; Patrick A Kupelian; Matthew B Rettig; Nicholas G Zaorsky; Alejandro Berlin; Jonathan D Tward; Brian J Davis; Robert E Reiter; Michael L Steinberg; David Elashoff; Eric M Horwitz; Rahul D Tendulkar; Derya Tilki; Johannes Czernin; Andrei Gafita; Tahmineh Romero; Jeremie Calais; Amar U Kishan
Journal:  JAMA Netw Open       Date:  2021-12-01

7.  A Phase 2/3 Prospective Multicenter Study of the Diagnostic Accuracy of Prostate Specific Membrane Antigen PET/CT with 18F-DCFPyL in Prostate Cancer Patients (OSPREY).

Authors:  Kenneth J Pienta; Michael A Gorin; Steven P Rowe; Peter R Carroll; Frédéric Pouliot; Stephan Probst; Lawrence Saperstein; Mark A Preston; Ajjai S Alva; Akash Patnaik; Jeremy C Durack; Nancy Stambler; Tess Lin; Jessica Jensen; Vivien Wong; Barry A Siegel; Michael J Morris
Journal:  J Urol       Date:  2021-02-26       Impact factor: 7.450

8.  Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study.

Authors:  Michael S Hofman; Nathan Lawrentschuk; Roslyn J Francis; Colin Tang; Ian Vela; Paul Thomas; Natalie Rutherford; Jarad M Martin; Mark Frydenberg; Ramdave Shakher; Lih-Ming Wong; Kim Taubman; Sze Ting Lee; Edward Hsiao; Paul Roach; Michelle Nottage; Ian Kirkwood; Dickon Hayne; Emma Link; Petra Marusic; Anetta Matera; Alan Herschtal; Amir Iravani; Rodney J Hicks; Scott Williams; Declan G Murphy
Journal:  Lancet       Date:  2020-03-22       Impact factor: 79.321
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.